Barinthus Biotherapeutics plc

NasdaqGM:BRNS Voorraadrapport

Marktkapitalisatie: US$56.4m

Barinthus Biotherapeutics Dividend

Dividend criteriumcontroles 0/6

Barinthus Biotherapeutics does not have a record of paying a dividend.

Belangrijke informatie

n/a

Dividendrendement

-1.8%

Terugkoop Rendement

Totaal aandeelhoudersrendement-1.8%
Toekomstig dividendrendementn/a
Dividendgroein/a
Volgende betaaldatum dividendn/a
Ex-dividenddatumn/a
Dividend per aandeeln/a
Uitbetalingsration/a

Recente dividendupdates

Geen updates

Recent updates

Is Barinthus Biotherapeutics (NASDAQ:BRNS) In A Good Position To Invest In Growth?

Aug 31
Is Barinthus Biotherapeutics (NASDAQ:BRNS) In A Good Position To Invest In Growth?

Here's Why We're Watching Barinthus Biotherapeutics' (NASDAQ:BRNS) Cash Burn Situation

Apr 05
Here's Why We're Watching Barinthus Biotherapeutics' (NASDAQ:BRNS) Cash Burn Situation

We Think Vaccitech (NASDAQ:VACC) Can Afford To Drive Business Growth

Jul 07
We Think Vaccitech (NASDAQ:VACC) Can Afford To Drive Business Growth

Vaccitech's (NASDAQ:VACC) Earnings Are Of Questionable Quality

Nov 17
Vaccitech's (NASDAQ:VACC) Earnings Are Of Questionable Quality

Vaccitech promotes Gemma Brown to CFO

Sep 20

Analysts Just Made An Incredible Upgrade To Their Vaccitech plc (NASDAQ:VACC) Forecasts

Aug 15
Analysts Just Made An Incredible Upgrade To Their Vaccitech plc (NASDAQ:VACC) Forecasts

Vaccitech plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Aug 13
Vaccitech plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Vaccitech GAAP EPS of $0.41, revenue of $17.06M

Aug 09

Growth Investors: Industry Analysts Just Upgraded Their Vaccitech plc (NASDAQ:VACC) Revenue Forecasts By 51%

May 19
Growth Investors: Industry Analysts Just Upgraded Their Vaccitech plc (NASDAQ:VACC) Revenue Forecasts By 51%

Vaccitech: Aiming For A Cure In Chronic Hepatitis B

Apr 03

Vaccitech: The Next Big Vaccine Trade

Jun 27

Vaccitech EPS misses by $0.69, beats on revenue

Jun 14

Stabiliteit en groei van betalingen

Dividenden ophalen

Stabiel dividend: Insufficient data to determine if BRNS's dividends per share have been stable in the past.

Groeiend dividend: Insufficient data to determine if BRNS's dividend payments have been increasing.


Dividendrendement versus markt

Barinthus Biotherapeutics Dividendrendement versus markt
Hoe verhoudt BRNS dividendrendement zich tot de markt?
SegmentDividendrendement
Bedrijf (BRNS)n/a
Markt onderkant 25% (US)1.5%
Markt Top 25% (US)4.5%
Gemiddelde industrie (Biotechs)2.2%
Analist prognose (BRNS) (tot 3 jaar)n/a

Opmerkelijk dividend: Unable to evaluate BRNS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Hoog dividend: Unable to evaluate BRNS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Winstuitkering aan aandeelhouders

Verdiendekking: Insufficient data to calculate BRNS's payout ratio to determine if its dividend payments are covered by earnings.


Contante uitbetaling aan aandeelhouders

Kasstroomdekking: Unable to calculate sustainability of dividends as BRNS has not reported any payouts.


Ontdek bedrijven met een sterk dividend